Oxidative Stress and Polycystic Ovary Syndrome: A Brief Review

Masoumeh Mohammadi, Masoumeh Mohammadi

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders, occurring in 5-10% women in reproductive ages. Despite a long history of studies on PCOS, its etiology is still unknown. Oxidative stress is now recognized to play a central role in the pathophysiology of many different disorders, including PCOS. Although intracellular reactive oxygen species (ROS) production and propagation are controlled by highly complex antioxidant enzymatic and non-enzymatic systems, understanding of mechanisms that oxidative stress is important to develop strategies for prevention and therapy of PCOS. This article reviews the literature data related to the mechanisms of oxidative stress in PCOS.

Keywords: Antioxidant; oxidative marker; oxidative stress; polycystic ovary syndrome; reactive oxygen species.

Conflict of interest statement

There are no conflicts of interest.

References

    1. Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Human Reprod Update. 2013;19:268–88.
    1. Zhang J, Fan P, Liu H, Bai H, Wang Y, Zhang F. Apolipoprotein AI and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Human Reprod. 2012;27:2484–93.
    1. Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. GynecolObstet Invest. 2010;69:274–80.
    1. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif. 1991;24:203–14.
    1. Allen RG, Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med. 2000;28:463–99.
    1. Droge, W Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.
    1. Seaver LC, Imlay JA. Are respiratory enzymes the primary sources of intracellular hydrogen peroxide? J Biol Chem. 2004;279:48742–50.
    1. Geiszt M, Kapus A, Német K, Farkas L, Ligeti E. Regulation of capacitative Ca2+ influx in human neutrophil granulocytes alterations in chronic granulomatous disease. JBiolChem. 1997;272:26471–8.
    1. Dvorakova M, Höhler B, Vollerthun R, Fischbach T, Kummer W. Macrophages: A major source of cytochrome b558 in the rat carotid body. Brain Res. 2000;852:349–54.
    1. Cheng G, Cao Z, Xu X, Van Meir EG, Lambeth JD. Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5. Gene. 2001;269:131–40.
    1. Dorsam G, Taher MM, Valerie KC, Kuemmerle NB, Chan JC, Franson RC. Diphenyleneiodium chloride blocks inflammatory cytokine-induced up-regulation of group IIA phospholipase A2 in rat mesangial cells. JPharmacolExp Ther. 2000;292:271–9.
    1. Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S, et al. Oxidative stress, prooxidants, and antioxidants: The interplay. Biomed Res Int. 2014;2014:761264.
    1. Bouayed J, Bohn T. Exogenous antioxidants—Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longevity. 2010;3:228–37.
    1. Al-Gubory KH, Fowler PA, Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. Int J Biochem Cell Biol. 2010;42:1634–50.
    1. Herrera E, Barbas C. Vitamin E: Action, metabolism and perspectives. J Physiol Biochem. 2001;57:43–56.
    1. Johnson LJ, Meacham SL, Kruskall LJ. The antioxidants--vitamin C, vitamin E, selenium, and carotenoids. J Agromedicine. 2003;9:65–82.
    1. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: Antioxidants and beyond. Am J Clin Nutr. 2005;81(1 Suppl):215S–7S.
    1. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol. 2003;101:1177–82.
    1. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, SattarN Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86:2453–5.
    1. Wang X, Martindale JL, Liu Y, HolbrookNJ The cellular response to oxidative stress: Influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J. 1998;333:291–300.
    1. Runchel C, Matsuzawa A, IchijoH Mitogen-activated protein kinases in mammalian oxidative stress responses. Antioxid Redox Signal. 2011;15:205–18.
    1. Brown MD, Sacks DB. Protein scaffolds in MAP kinase signalling. Cell Signal. 2009;21:462–9.
    1. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer. Pharmacol Rev. 2008;60:261–310.
    1. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 2012;12:159–69.
    1. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.
    1. Akbarali HI. Oxidative stress and ion channels. In: Laher I, editor. Systems Biology of Free Radicals and Antioxidants. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. pp. 355–73.
    1. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on female reproduction: A review. Reprod Biol Endocrinol. 2012;10:49.
    1. Rashidi B, Haghollahi F, Shariat M, Zayerii F. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: A pilot study. Taiwan J Obstet Gynecol. 2009;48:142–7.
    1. Cabiscol E, Ros J. Oxidative damage to proteins: structural modifications and consequences in cell function. Redox proteomics: From protein modification to cellular dysfunction and disease. 2006:399–471.
    1. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med. 2006;10:389–406.
    1. Kaya C, Erkan AF, Cengiz SD, Dünder I, Demirel ÖE, Bilgihan A. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: Relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril. 2009;92:1372–7.
    1. Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001;306:1–17.
    1. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336–40.
    1. Torun AN, Vural M, Cece H, Camuzcuoglu H, Toy H, Aksoy N. Paraoxonase-1 is not affected in polycystic ovary syndrome without metabolic syndrome and insulin resistance, but oxidative stress is altered. Gynecol Endocrinol. 2011;27:988–92.
    1. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J. 2003;17:1195–214.
    1. Dinger Y, Akcay T, Erdem T, Ilker Saygili E, Gundogdu S. DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. Scand J Clin Lab Invest. 2005;65:721–8.
    1. Dib M, Garrel C, Favier A, Robin V, Desnuelle C. Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease? JNeurol. 2002;249:367–74.
    1. Northrop-Clewes CA, Thurnham DI. Monitoring micronutrients in cigarette smokers. Clinica Chimica Acta. 2007;377:14–38.
    1. Davey MW, Stals E, Panis B, Keulemans J, Swennen RL. High-throughput determination of malondialdehyde in plant tissues. Anal Biochem. 2005;347:201–7.
    1. Kuscu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009;88:612–7.
    1. Zhang D, Luo W, Liao H, Wang C, Sun Y. The effects of oxidative stress to PCOS. Sichuan da xue xue bao. Yi xue ban= Journal of Sichuan University. Medical Science edition. 2008;39:421–3.
    1. Dursun P, Demirtaş E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: An additional risk factor for atherosclerotic heart disease in patients with PCOS? Human Reprod. 2006;21:104–8.
    1. Palacio J, Iborra A, Ulcova-Gallova Z, Badia R, Martinez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. ClinExp Immunol. 2006;144:217–22.
    1. Sabuncu T, Vural H, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34:407–13.
    1. Tuso P, Stoll SR, Li WW. A plant-based diet, atherogenesis, and coronary artery disease prevention. Perm J. 2015;19:62–7.
    1. Hassani F, Karami M, Jalali Nadoushan MR, Yazdi PE. Nitric Oxide-Induced Polycystic Ovaries in The Wistar Rat. Int J Fertil Steril. 2012;6:111–6.
    1. Karabulut AB, Cakmak M, Kiran RT, Sahin I. Oxidative stress status, metabolic profile and cardiovascular risk factors in patients with polycystic ovary syndrome. Med-Science, 2012;1:27–34.
    1. Willis G, Hocking R, Udiawar M, Rees A, James P. Oxidative stress and nitric oxide in polycystic ovary syndrome. Nitric Oxide, 2012;27:S28.
    1. Nacul AP, Andrade CD, Schwarz P, de Bittencourt PI, Jr, Spritzer PM. Nitric oxide and fibrinogen in polycystic ovary syndrome: Associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol. 2007;133:191–6.
    1. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. CurrPharm Des. 2008;14:987–9.
    1. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Chemical Res Toxicology. 1997;10:485–94.
    1. Thorpe SR, Baynes JW. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging. 1996;9:69–77.
    1. Garg D, Merhi Z. Relationship between advanced glycation end products and steroidogenesis in PCOS. Reprod Biol Endocrinol. 2016;14:71.
    1. Diamanti-Kandarakis E. Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:e3.
    1. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005;62:37–43.
    1. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, Kandaraki E, Levidou G, Papalois A, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl) 2007;85:1413–20.
    1. Tantalaki E, Piperi C, Livadas S, Kollias A, Adamopoulos C, Koulouri A, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS) Hormones (Athens) 2014;13:65–73.
    1. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: Molecular mechanisms and clinical implications. J Cardiol. 2012;59:235–42.
    1. Baskol G, Aygen E, Erdem F, Caniklioglu A, Narin F, Sahin Y, et al. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidase activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2012;91:326–30.
    1. Isık H, Aynıoglu O, Tımur H, Sahbaz A, Harma M, Can M, et al. Is Xanthine oxidase activity in polycystic ovary syndrome associated with inflammatory and cardiovascular risk factors? J Reprod Immunol. 2016;116:98–103.
    1. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. FertilSteril. 2003;80:123–7.
    1. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: Correlations with endocrine and screening parameters. GynecolObstetInvest. 2008;65:233–9.
    1. Barondeau DP, Kassmann CJ, Bruns CK, Tainer JA, Getzoff ED. Nickel superoxide dismutase structure and mechanism. Biochemistry. 2004;43:8038–47.
    1. Seleem AK, El Refaeey AA, Shaalan D, Sherbiny Y, Badawy A. Superoxide dismutase in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection. JAssistReprodGenet. 2014;31:499–504.
    1. Savic-Radojevic A, Bozic Antic I, Coric V, Bjekic-Macut J, Radic T, Zarkovic M, et al. Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome. Hormones (Athens) 2015;14:101–8.
    1. Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal. 2009;11:2685–700.
    1. Hammond CL, Lee TK, Ballatori N. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J Hepatol. 2001;34:946–54.
    1. Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Invest. 2012;35:317–21.
    1. Mohan S, Priya V. Lipid peroxidation, glutathione, ascorbic acid, vitamin E, antioxidant enzyme and serum homocysteine status in patients with polycystic ovary syndrome. Biol Med. 2009;1:44–9.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi